Want to see CNTN full AI Analyst Report?
CNTN Stock Chart & Stats
$2.23
-$0.07(-3.02%)
At close: 4:00 PM EST
$2.23
-$0.07(-3.02%)
Day’s Range― - ―
52-Week Range$1.66 - $6.89
Previous CloseN/A
VolumeN/A
Average Volume (3M)885.88K
Market Cap
$148.21M
Enterprise Value$574.32M
Total Cash (Recent Filing)$37.24M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding79,681,360
10 Day Avg. Volume872,891
30 Day Avg. Volume885,882
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.24
Price to Sales (P/S)0.00
P/FCF Ratio-1.04
Enterprise Value/Market Cap3.88
Enterprise Value/Revenue383.94
Enterprise Value/Gross Profit383.94
Enterprise Value/Ebitda-7.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free CapitalizationA debt-free balance sheet with substantial equity and assets gives Canton greater financial flexibility than a highly leveraged peer. This capitalization can help absorb operating volatility and preserve options for restructuring, investment, or other strategic actions over the coming quarters.
Strategic Divestiture ProceedsThe Gravitas divestiture converts ownership of a clinical-stage subsidiary into a contractual note and potential milestone economics. That structure can provide interest income and retained upside while reducing direct operating exposure to the divested biotech business.
Selected Asset RetentionRetaining selected bispecific antibody assets preserves a measure of participation in potential biotech value creation despite the subsidiary sale. This creates strategic optionality while allowing Canton to refocus its structure rather than relinquishing every related development asset.
Bears Say
Minimal Revenue And Deep LossesThe very small revenue base does not currently support the scale of reported losses, indicating weak operating leverage and limited evidence of a self-sustaining commercial model. Persistently widening losses can erode capital and increase the importance of future execution or funding.
Persistent Cash BurnNegative operating cash flow across every reported period shows that ongoing activities are consuming rather than generating cash. Continued free-cash-flow deficits can reduce financial flexibility over the next several quarters and require external funding or asset monetization.
Reduced Direct Biotech OwnershipSelling the clinical-stage subsidiary materially changes Canton’s direct operating exposure to its biotech pipeline. Although note and milestone economics remain, the transaction may reduce control over development execution and makes future value dependent on retained assets and contractual proceeds.
Canton Strategic Holdings News
CNTN FAQ
What was Canton Strategic Holdings’s price range in the past 12 months?
Canton Strategic Holdings lowest stock price was $1.66 and its highest was $6.89 in the past 12 months.
What is Canton Strategic Holdings’s market cap?
Canton Strategic Holdings’s market cap is $148.21M.
When is Canton Strategic Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Canton Strategic Holdings’s earnings last quarter?
Currently, no data Available
Is Canton Strategic Holdings overvalued?
According to Wall Street analysts Canton Strategic Holdings’s price is currently Overvalued.
Does Canton Strategic Holdings pay dividends?
Canton Strategic Holdings does not currently pay dividends.
What is Canton Strategic Holdings’s EPS estimate?
Canton Strategic Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Canton Strategic Holdings have?
Canton Strategic Holdings has 79,681,360 shares outstanding.
What happened to Canton Strategic Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Canton Strategic Holdings?
Currently, no hedge funds are holding shares in CNTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Canton Strategic Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
CNTN Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 37.5K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.86%
12-Months-Change
Fundamentals
Return on Equity
-29.54%
Trailing 12-Months
Asset Growth
9999.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Canton Strategic Holdings
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Technical Analysis
CervoMed
―
―
Champions Oncology
―
Pelthos Therapeutics
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.17% Insiders
0.97% Mutual Funds
0.06% Other Institutional Investors
89.40% Public Companies and
Individual Investors